Antibiotic resistance, plasmid content and auxotypes of Neisseria gonorrhoeae in Greece

1988 ◽  
Vol 21 (5) ◽  
pp. 571-579 ◽  
Author(s):  
L. Mavrommati ◽  
E. Tzetepi ◽  
A. Sima ◽  
G. Tzanakaki ◽  
A. Kokia ◽  
...  
1990 ◽  
Vol 36 (1) ◽  
pp. 64-67 ◽  
Author(s):  
Jo-Anne R. Dillon ◽  
Maria Carballo

Between October 1987 and June 1989, 84 isolates of Neisseria gonorrhoeae carrying the TetM resistance determinant (TRNG) were received at the Laboratory Centre for Disease Control, Ottawa, from six Canadian provinces and were characterized into classes based on auxotype, serovar and plasmid content. One-fifth (17/84) of the TRNG were also penicillinase producing (PPNG). The PPNG–TRNG isolates comprised six classes based on auxotype, serovar, and plasmid content. Most (16/17) PPNG–TRNG carried 3.2-MDa β-lactamase plasmids and the 25.2-MDa TetM-containing plasmid. We report, for the first time, the association of a 4.5-MDa β-lactamase plasmid with the 25.2-MDa plasmid in a clinical TRNG isolate. Non-PPNG TRNG isolates comprised 11 classes based on auxotype, serovar, and plasmid content, including two previously unreported auxotype–serovar classes, P/IB-26 and P/IB-20. Key words: Neisseria gonorrhoeae, tetracycline resistance, plasmid, epidemiology.


2020 ◽  
Vol 58 (4) ◽  
Author(s):  
Ellen N. Kersh ◽  
Cau D. Pham ◽  
John R. Papp ◽  
Robert Myers ◽  
Richard Steece ◽  
...  

ABSTRACT U.S. gonorrhea rates are rising, and antibiotic-resistant Neisseria gonorrhoeae (AR-Ng) is an urgent public health threat. Since implementation of nucleic acid amplification tests for N. gonorrhoeae identification, the capacity for culturing N. gonorrhoeae in the United States has declined, along with the ability to perform culture-based antimicrobial susceptibility testing (AST). Yet AST is critical for detecting and monitoring AR-Ng. In 2016, the CDC established the Antibiotic Resistance Laboratory Network (AR Lab Network) to shore up the national capacity for detecting several resistance threats including N. gonorrhoeae. AR-Ng testing, a subactivity of the CDC’s AR Lab Network, is performed in a tiered network of approximately 35 local laboratories, four regional laboratories (state public health laboratories in Maryland, Tennessee, Texas, and Washington), and the CDC’s national reference laboratory. Local laboratories receive specimens from approximately 60 clinics associated with the Gonococcal Isolate Surveillance Project (GISP), enhanced GISP (eGISP), and the program Strengthening the U.S. Response to Resistant Gonorrhea (SURRG). They isolate and ship up to 20,000 isolates to regional laboratories for culture-based agar dilution AST with seven antibiotics and for whole-genome sequencing of up to 5,000 isolates. The CDC further examines concerning isolates and monitors genetic AR markers. During 2017 and 2018, the network tested 8,214 and 8,628 N. gonorrhoeae isolates, respectively, and the CDC received 531 and 646 concerning isolates and 605 and 3,159 sequences, respectively. In summary, the AR Lab Network supported the laboratory capacity for N. gonorrhoeae AST and associated genetic marker detection, expanding preexisting notification and analysis systems for resistance detection. Continued, robust AST and genomic capacity can help inform national public health monitoring and intervention.


2012 ◽  
Vol 52 (5) ◽  
pp. 259-266 ◽  
Author(s):  
Jong Earn Yu ◽  
Mi Young Cho ◽  
Jin-woo Kim ◽  
Ho Young Kang

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Daouda A. K. Traore ◽  
Jessica A. Wisniewski ◽  
Sarena F. Flanigan ◽  
Paul J. Conroy ◽  
Santosh Panjikar ◽  
...  

Plasmid ◽  
2000 ◽  
Vol 43 (1) ◽  
pp. 35-48 ◽  
Author(s):  
David Stockwell ◽  
Vera Lelianova ◽  
Teresa Thompson ◽  
Walter B Dempsey

Sign in / Sign up

Export Citation Format

Share Document